Get the Stockscreener App
52.45
0.25%
0.13
After Hours:
52.45
Biomarin Pharmaceutical Inc stock is traded at $52.45, with a volume of 2.24M.
It is up +0.25% in the last 24 hours and down -3.03% over the past month.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
See More
Previous Close:
$52.32
Open:
$52.585
24h Volume:
2.24M
Relative Volume:
1.07
Market Cap:
$10.07B
Revenue:
$2.95B
Net Income/Loss:
$523.88M
P/E Ratio:
19.50
EPS:
2.69
Net Cash Flow:
$620.18M
1W Performance:
-5.68%
1M Performance:
-3.03%
6M Performance:
-7.69%
1Y Performance:
-25.44%
1-Day Range:
$51.85
$52.90
1-Week Range:
$51.78
$56.26
52-Week Range:
$51.78
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
52.45 | 10.05B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | H.C. Wainwright | Neutral |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Feb-24-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
Can BioMarin Pharmaceutical Inc. stock hit analyst price targetsJuly 2025 EndofMonth & Low Risk Entry Point Tips - newser.com
What MACD signals say about BioMarin Pharmaceutical Inc.Market Weekly Review & Expert Curated Trade Ideas - newser.com
Price momentum metrics for BioMarin Pharmaceutical Inc. explainedMarket Activity Summary & Safe Investment Capital Preservation Plans - newser.com
BioMarin Pharmaceutical Inc. stock outlook for YEARJuly 2025 Patterns & Daily Profit Maximizing Tips - newser.com
Can BioMarin Pharmaceutical Inc. stock reach $100 price targetMarket Movement Recap & Weekly Market Pulse Alerts - newser.com
How to manage a losing position in BioMarin Pharmaceutical Inc.Long Setup & Weekly Setup with ROI Potential - newser.com
How strong is BioMarin Pharmaceutical Inc. stock balance sheetJuly 2025 PostEarnings & High Yield Stock Recommendations - newser.com
What data driven models say about BioMarin Pharmaceutical Inc.’s futureStock Surge & Risk Managed Investment Strategies - newser.com
Understanding BioMarin Pharmaceutical Inc.’s price movementQuarterly Growth Report & Daily Oversold Stock Bounce Ideas - newser.com
Real time social sentiment graph for BioMarin Pharmaceutical Inc.2025 Fundamental Recap & AI Driven Stock Reports - newser.com
Ascendis Pharma Develops Sustained-Release Therapy to Compete with BioMarin’s Voxzogo for Achondroplasia Treatment - geneonline.com
Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause - BioSpace
Board of the Pension Protection Fund Invests $445,000 in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Aberdeen Group plc Has $54.04 Million Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
BioMarin Pharmaceutical (NASDAQ:BMRN) Sets New 12-Month LowTime to Sell? - MarketBeat
Leerink Partnrs Has Negative Outlook of BMRN Q1 Earnings - MarketBeat
Callan Family Office LLC Purchases 47,264 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Biomarin Pharmaceutical stock hits 52-week low at 52.47 USD By Investing.com - Investing.com Nigeria
10x Genomics, BioMarin Pharmaceutical, AMN Healthcare Services, Illumina, and Moderna Stocks Trade Down, What You Need To Know - Yahoo Finance
MarketsFinancial Advisors - FinancialContent
Biomarin Pharmaceutical stock hits 52-week low at 52.47 USD - Investing.com India
Relative strength of BioMarin Pharmaceutical Inc. in sector analysisQuarterly Investment Review & Community Trade Idea Sharing - newser.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $119.00 - MarketBeat
BioMarin Pharmaceutical's (BMRN) "Sell (D+)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Duchenne Muscular Dystrophy Drugs Market Global Forecast - GlobeNewswire
Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion - Yahoo Finance
Where is BioMarin Pharmaceutical (BMRN) Headed According to Analysts? - MSN
Biomarin Pharmaceutical expects Q3 will include acquired IPR&D charges of about $221 million - MarketScreener
BioMarin projects $221 million IPR&D charge from Inozyme acquisition - Investing.com
AAV Gene Therapy Market Size to Skyrocket at 40.1% CAGR by 2034 - GlobeNewswire Inc.
14 Biotech Stocks with High Potential - Insider Monkey
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - sharewise.com
Real time alert setup for BioMarin Pharmaceutical Inc. performanceIPO Watch & Reliable Intraday Trade Plans - newser.com
How BioMarin Pharmaceutical Inc. stock performs in stagflationM&A Rumor & Long-Term Safe Investment Ideas - newser.com
Should Positive Phase 3 PALYNZIQ Results Prompt Action From BioMarin (BMRN) Investors? - Sahm
Robeco Institutional Asset Management B.V. Increases Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc.’s (BMRN) Phenylketonuria Candidate Drug Impresses in Phase 3 Trials - MSN
Can BioMarin (BMRN) Turn PALYNZIQ Success Into a Stronger Rare Disease Growth Story? - Yahoo Finance
J. Safra Sarasin Holding AG Boosts Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Is BioMarin Pharmaceutical Inc. stock a safe buy before earningsMarket Weekly Review & Momentum Based Trading Ideas - newser.com
BioMarin Pharmaceutical (BMRN): Evaluating Valuation as PALYNZIQ Clinical Success Contrasts With 52-Week Share Price Low - Sahm
How institutional ownership impacts BioMarin Pharmaceutical Inc. stockPortfolio Return Report & Free Accurate Trade Setup Notifications - newser.com
The Top 12 Companies Hiring in Biopharma Now - BioSpace
Growth and Pipeline Keep BioMarin Pharmaceutical Inc. (BMRN) Attractive for Investors - Insider Monkey
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):